Abstract
This study was addressed to evaluate the temporospatial pattern of key components of the kallikreinkinin system in human uterus in luteal phase (n=7), early pregnancy (isolated spontaneous abortions, n = 11; ectopic pregnancies, n=9), idiopathic preterm deliveries (n=5), and term gestations (n=12). Tissue kallikrein mRNA and protein and the type 2 bradykinin receptor (B2R) protein were expressed in luminal and glandular epithelium and in endothelial cells of stromal and myometrial blood vessels, while tissue kallikrein mRNA and B2R, but not tissue kallikrein protein, were observed in decidual cells and in arteriolar and myometrial muscle. A greater signal intensity for tissue kallikrein mRNA and protein and of B2R protein was observed in the early pregnancy samples. The sites and variations of the tissue kallikrein mRNA and protein and of the B2R protein in the human uterus and in fallopian tubes during the luteal phase and in pregnancy coincide with those described for other vasoactive effectors such as nitric oxide, prostacyclins, growth factors, and renin. The uterine localization of the main enzyme and receptor of the tissue kallikrein-kinin system in key sites for embryo attachment, implantation, placentation, maintenance of placental blood flow, and parturition supports the notion that the kallikrein-kinin system participates in these processes, probably through vasodilation, increased vasopermeability, enhanced matrix degradation, stimulation of cell proliferation, and myometrial contractility.
Similar content being viewed by others
References
Bhoola, K. D., Figueroa, C. D., and Worthy, K. (1992). Pharmacol. Rev. 44, 1–80.
Regoli, D. and Barabe, J. (1980). Pharmacol. Rev. 32, 1–46.
Marceau, F., Hess, J. F., and Bachvarov, D. R. (1998). Pharmacol. Rev. 50, 357–386.
Valdés, G., Corthorn, J., Scicli, G. A., Gaete, V., Soto, J., Ortiz, M. E., Foradori, A., and Saed, G. A. (1993). Biol. Reprod. 49, 802–808.
Valdés, G., Figueroa, C. D., and Corthorn, J. (1996). Biol. Reprod. 55, 236–245.
Figueroa, C. D., Novoa, U., Valdés, G., Corthorn, J., and Müller-Esterl, W. (1997). Immunopharmacology 36, 127–133.
Corthorn, J. and Valdés, G. (1994). Biol. Reprod. 50, 1261–1664.
Corthorn, J. and Valdés, G. (1997). Biol. Reprod. 56, 1432–1438.
Figueroa, C. D., Chacón, C., Corthorn, J., Ehrenfeld, P., Müller-Esterl, W., and Valdés, G. (2001). Biol. Reprod. 64, 1590–1599.
Clements, J., Mukhtar, A., Erlich, A., and Yap, B. (1994). Braz. J. Med. Biol. Res. 27, 1855–1863.
Clements, J. and Mukhtar, A. (1994). J. Clin. Endocrinol. Metab. 78, 1536–1539.
Malofiejew, M. (1973). Biochem. Pharmacol. 22, 123–127.
Valdés, G., Chacón, C., Corthorn, J., Figueroa, C. D., and Germain, A. M. (2001). Endocrine 14, 197–204.
Vonnahme, K. A., Malayer, J. R., Spivey, H. O., Ford, S. P., Clutter, A., and Geisert, R. D. (1999). Biol. Reprod. 61, 1235–1241.
Denker, H. W. and Tyndale-Biscoe, C. H. (1986). Cell Tissue Res. 246, 279–291.
Lala, P. K. and Graham, C. H. (1990). Cancer Metastasis Rev. 9, 369–379.
Desrivieres, S., Lu, H., Peyri, N., Soria, C., Legrand, Y., and Menashi, S. J. (1993). Cell. Physiol. 157, 587–593.
Menashi, S., Fridman, R., Desrivieres, S., Lu, H., Legrand, Y., and Soria, C. (1994). Ann. NY Acad. Sci. 732, 466–468.
Hulboy, D. L., Rudolph, L. A., and Matrisian, L. M. (1997). Mol. Hum. Reprod. 3, 27–45.
Figueroa, C. D., Marchant, A., Novoa, U., Försterman, U., Jarnagin, K., Schölkens, B., and Müller-Esterl, W. (2001). Hypertension 37, 110–120.
Honing, M. L. H., Smits, P., Morrison, P. J., and Rabelink, T. J. (2000). Hypertension 35, 1314–1318.
Cockroft, J. R., Chowiencyk, P. J., Brett, S. E., and Ritter, J. M. (1994). Br. J. Clin. Pharmacol. 38, 307–310.
Yamasaki, S., Sawada, S., Komatsu, S., et al. (2000). Hypertension 36, 201–207.
Telfer, J. F., Irvine, G. A., Kohnen, G., Campbell, S., and Cameron, I. T. (1997). Mol. Hum. Reprod. 3, 69–75.
Rehbock, J., Chondromatidou, A., Buchinger, P., and Hermann, A. (1996). Immunopharmacology 33, 164–166.
Rehbock, J., Chondromatidou, A., Miska, K., Buchinger, P., and Hermann, A. (1997). Immunopharmacology 36, 135–141.
Endo, T., Fulane, H., Kanaya, M., Mizunuma, M., Fujii, M., Yamamoto, H., Tanaka, S., and Hashimoto, M. (1991). J. Endocrinol. 131, 313–318.
Bonney, R. C., Beesley, J. S., Rahman, C., and Franks, S. (1993). Prostaglandins Leukotrienes Essent. Fatty Acids 48, 253–260.
Trautman, M. S., Edwis, S. S., Collmer, D., Dudley, D. J., Simmons, D., and Mitchell, M. D. (1999). Placenta 17, 239–245.
Moses, E. K., Freed, K. A., Brennecke, S. P., and Rice, G. E. (1998). Placenta 19, 35–40.
Rohrwasser, A., Morgan, T., Dillon, H. F., et al. (1999). Hypertension 34, 1265–1274.
Morgan, T., Craven, C., and Ward, K. (1998). Hypertension 32, 683–687.
Li, C., Ansari, R., and Sha, D. (2000). Hypertension 36, 154–164.
Athanassiades, A., Hamilton, G. S., and Lala, P. K. (1998). Biol. Reprod. 59, 643–654.
Clark, D. E., Smith, S. K., Sharkey, A. M., and Charnoj-Jones, D. S. (1996). Hum. Reprod. 11, 1090–1098.
Whalley, E. T. and Riley, A. J. (1978). J. Endocrinol. 77, 20,21.
Valdés, G., Corthorn, J., Oyarzún, E., Berríos, C., Foradori, A., Germain, A. M., and Villarroel, L. (1998). Prenat. Neonat. Med. 3, 474–481.
Germain, A. M., Carvajal, J., Sánchez, M., Valenzuela, G. J., Tsunekawa, H., and Chuaqui, B. (1999). Obstet. Gynecol. 94, 284–289.
Fukushima, D., Kitamura, N., and Nakashini, S. (1985). Biochemistry 24, 8037–8043.
Chen, L., Richards, G., Chao, L., and Chao, J. (1995). Biochem. J. 307, 481–486.
Schmitz, G. G., Walter, T., Seibl, R., and Kessler, C. (1991). Anal. Biochem. 192, 222–231.
Cohen, J. (1968). Psychol. Bull. 70, 213–220.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Valdés, G., Germain, A.M., Corthorn, J. et al. Tissue kallikrein and bradykinin B2 receptor in human uterus in luteal phase and in early and late gestation. Endocr 16, 207–215 (2001). https://doi.org/10.1385/ENDO:16:3:207
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:16:3:207